Avtor/Urednik		Atalay, G; Dirix, L; Biganzoli, L; Beex, L; Nooij, M; Cameron, D; Lohrisch, C; Čufer, T; Lobelle, JP; Mattiaci, MR
Naslov		The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'
Tip		članek
Vir		Ann Oncol
Vol. in št.		Letnik 15, št. 2
Leto izdaje		2004
Obseg		str. 211-7
Jezik		eng
Abstrakt		Background: The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oesfrogens, has become increasingly important in postmenopausal women with hormonedependent breast cancer. So far, data related to the effect of AIs on lipid profile in postmenopausal women is scarce. This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients. Patients and methods: The EORTC trial 10951 randomised 122 postmenopausal breast cancer patients to exemestane (E) 25 mg (n = 62) or tamoxifen (T) 20 mg (n = 60) once daily as a first-line treatment in the metastatic setting. Exemestane showed promising results in all the primary efficacy end points of the trial (response rate, clinical benefit rate and response duration), and it was well tolerated with low incidence of serious toxicity. As a secondary end point of this phase II trial, serum triglycerides (TRG), high-density lipoprotein cholesterol (HDL), total cholesterol (TC), lipoprotein a (Lip a), and apolipoproteins (Apo) B and A 1 were measured at baseline and while on therapy (at 8, 24 and 48 weeks) to assess the impact of exemestane and tamoxifen on serum lipid profiles. Of the 122 randomised patients, those who had baseline and at least one other lipid assessment are included in the present analysis. The patients who received concomitant drugs that could affect lipid profile are included only if these drugs were administered throughout the study treatment. Increase or decrease in lipid parameters within 20% of baseline were considered as non-significant and thus unchanged. (Abstract truncated at 2000 characters)
Deskriptorji		BREAST NEOPLASMS ANTINEOPLASTIC AGENTS, HORMONAL ANDROSTADIENES CHOLESTEROL TAMOXIFEN AGE FACTORS RISK FACTORS POSTMENOPAUSE NEOPLASM METASTASIS AROMATASE ARTERIOSCLEROSIS ENZYME INHIBITORS LIPIDS